South Korea provides advanced therapies for severe hemolytic anemia including monoclonal antibodies, complement inhibitors, and targeted immunotherapy. JCI-accredited tertiary centers in Seoul utilize Rituximab for refractory cases and Eculizumab for complement-mediated conditions. Specialized protocols include plasmapheresis and stem cell transplantation for severe immune-mediated anemias.
- Targeted biologics: Rituximab and Ravulizumab treat severe or refractory autoimmune cases.
- Complement inhibition: Eculizumab manages hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) cases.
- Cellular therapy: CD19 CAR T-cell therapy is an emerging option for multi-refractory anemia.
- Advanced interventions: Plasmapheresis rapidly reduces autoantibodies during acute, life-threatening hemolytic crises.
Bookimed Expert Insight: Severance Hospital and Gangnam Severance Hospital both hold JCI and KOIHA certifications. This dual accreditation confirms they meet both international safety standards and strict Korean quality metrics. These centers manage high patient volumes, with Severance alone serving 1.6 million outpatients annually. Such high volume ensures hematologists are experienced in managing rare, life-threatening transfusion complications.
Patient Consensus: Patients emphasize finding the specific cause before starting treatment. They advise requesting a dedicated hematology consult rather than general anemia care. Most note that while transfusions are vital, long-term success requires immunotherapy like Rituximab.